EMEA-002057-PIP01-16
Key facts
| Active substance |
5-(4-Fluoro-1-benzothiophen-2-yl)-8-methyl-1,9-dihydro-2H-[1,3]oxazolo[4,5-H][2,3]benzodiazepin-2-one (S44819)
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0286/2017
|
| PIP number |
EMEA-002057-PIP01-16
|
| Pharmaceutical form(s) |
Powder for oral suspension
|
| Condition(s) / indication(s) |
Treatment of ischemic stroke to improve recovery
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Les Laboratoires Servier
Tel. + 33 1 55 72 60 00
E-mail: mail.pip.enquiries@servier.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|